These reports highlight the clinical potential of targeting E-cadherin expression and corroborate our observation that downregulation of E-cadherin by celecoxib was accompanied by attenuated tumor growth, reduction in cluster-CTCs and lung metastases, and increased sensitivity to paclitaxel treatment. This evidence concerns the gene CDH1 and neoplasm.